<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284814</url>
  </required_header>
  <id_info>
    <org_study_id>KME 89/07/17</org_study_id>
    <nct_id>NCT03284814</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of CoQ10 Formulations in Healthy Elderly Adults</brief_title>
  <acronym>CoQ10-01</acronym>
  <official_title>Single-dose and Multiple-dose Comparative Bioavailability Study of Three CoQ10 Formulations in Healthy Elderly Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutrition Institute, Slovenia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vizera d.o.o.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Valens Int. d.o.o., Slovenija</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MEDEDUS, Ljubljana, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nutrition Institute, Slovenia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The single-center, randomized, open-label, three-period crossover bioavailability study will
      include 21 subjects who will test three CoQ10 formulations. Subjects will test 3 formulations
      of single dose CoQ10 within first 3 weeks to assess bioavailability, which will be followed
      with 2 weeks of continuous administration of one of study formulations to demonstrate and
      assesse multiple-dose profile of CoQ10.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 19, 2017</start_date>
  <completion_date type="Anticipated">October 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Three-period crossover bioavailability study will include 21 subjects who will test three CoQ10 formulations. Subjects will test 3 formulations of single dose CoQ10 within first 3 weeks to assess bioavailability, which will be followed with 2 weeks of continuous administration of one of study formulations to demonstrate and assesse multiple-dose profile of CoQ10.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improved single dose bioavailability of IP (in comparison to SP)</measure>
    <time_frame>48 hours</time_frame>
    <description>Relative bioavailability between the investigational and standard product expressed as ratio of AUC0-48h (area under the plasma concentration curve from the administration time to the last observation point, i.e. 48h) of total CoQ10 plasma concentrations above the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improved plasma CoQ10 level after multiple dose study for IP (in comparison to SP)</measure>
    <time_frame>14 days</time_frame>
    <description>Ratio between total CoQ10 trough plasma concentrations after multiple-dose application on day 14 (CMIN,day14) between the investigational and standard product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparable single dose bioavailability of IP (in comparison to CP)</measure>
    <time_frame>48 hours</time_frame>
    <description>Relative bioavailability between the investigational product and comparator expressed as ratio of AUC0-48h of total CoQ10 plasma concentrations above the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparable plasma CoQ10 level after multiple dose study for IP (in comparison to CP)</measure>
    <time_frame>14 days</time_frame>
    <description>Ratio between total CoQ10 trough plasma concentrations after multiple-dose application on day 14 (CMIN,day14) between the investigational product and comparator.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Bioavailability of Coenzyme Q10</condition>
  <arm_group>
    <arm_group_label>Standard product group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparative product group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational product group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Standard product (SP)</intervention_name>
    <description>hard capsules, 100 mg</description>
    <arm_group_label>Standard product group</arm_group_label>
    <arm_group_label>Comparative product group</arm_group_label>
    <arm_group_label>Investigational product group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Comparative product (CP)</intervention_name>
    <description>soft-gel capsules, 100 mg</description>
    <arm_group_label>Standard product group</arm_group_label>
    <arm_group_label>Comparative product group</arm_group_label>
    <arm_group_label>Investigational product group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Investigational product (IP)</intervention_name>
    <description>syrup, 100 mg</description>
    <arm_group_label>Standard product group</arm_group_label>
    <arm_group_label>Comparative product group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multiple dose intervention with Standard product (SP)</intervention_name>
    <description>hard capsules, 100 mg - 14 days</description>
    <arm_group_label>Standard product group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multiple dose intervention with Comparative product (CP)</intervention_name>
    <description>soft-gel capsules, 100 mg - 14 days</description>
    <arm_group_label>Comparative product group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multiple dose intervention with Investigational product (IP)</intervention_name>
    <description>syrup, 100 mg - 14 days</description>
    <arm_group_label>Investigational product group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject Informed consent form (ICF) is singed

          -  Aged between 65 and 74 years at the time of the signature of ICF

          -  A body mass index between 20 and 29 kg/m2

          -  Healthy, meaning absence of any prescribed medication for a month prior to the
             inclusion to the study and during the study

          -  Willing to avoid a consumption of any food supplements except vitamin D and calcium at
             least 2 weeks before and during the study

          -  Consumption of dairy and cereal products (standardised breakfast will include low
             lactose dairy and bread)

          -  Willing to follow all study procedures, including attending all site visits (including
             sessions during which a venous line will be inserted for blood sampling), and keeping
             a diary for the time of multiple-dose study (to follow their compliance and
             palatability)

        Exclusion Criteria:

          -  Intake of any prescribed medication within 2 weeks of the beginning of the study

          -  Intake of any food supplements within 2 weeks of the beginning of the study, except
             vitamin D and calcium

          -  Hypotension

          -  Any clinically significant history of serious digestive tract, liver, kidney,
             cardiovascular or hematological disease, diabetes

          -  Gastrointestinal disorders or other serious acute or chronic diseases

          -  Known lactose/gluten intolerances/ food allergies (limitation for standardisation of
             meals)

          -  Inadequate veins (in the opinion of the investigator) or known contraindication to
             placement of a dedicated peripheral line for venous blood withdrawal

          -  Known drug and/or alcohol abuse

          -  Using any form of nicotine or tobacco

          -  Mental incapacity that precludes adequate understanding or cooperation

          -  Participation in another investigational study or blood donation within 3 months prior
             to or during this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Pravst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrition Institute, Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Snežana Kocijančič</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEDEDUS, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Igor Pravst, PhD</last_name>
    <phone>+386 590 68871</phone>
    <email>igor.pravst@nutris.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MEDEDUS, Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Snežana Kocijančič</last_name>
      <phone>+386 (0) 1 235 50 10</phone>
      <email>snezana.kocijancic@guest.arnes.si</email>
    </contact>
    <investigator>
      <last_name>Snežana Kocijančič</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nutrition Institute, Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Pravst, PhD</last_name>
      <phone>+386 (0) 590 68870</phone>
      <email>igor.pravst@nutris.org</email>
    </contact>
    <investigator>
      <last_name>Igor Pravst, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vizera d.o.o., Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojca Fir</last_name>
      <phone>+386 (0)1 600 22 41</phone>
      <email>mojca.fir@vizera.eu</email>
    </contact>
    <investigator>
      <last_name>Mojca Miholič</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nutrition Institute, Slovenia</investigator_affiliation>
    <investigator_full_name>Snežana Kocijančič</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>coenzyme q10</keyword>
  <keyword>single dose bioavailability</keyword>
  <keyword>multiple dose bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

